Faith, Sing

Director, Corporate And Commercial Lawyer fsLAW

Government and Public Sector , Logistics , Media and Entertainment




Government and Public Sector


Media and Entertainment





General Corporate

Capital Markets and Securities

Mergers and Acquisitions

Customer Type

Individuals & Companies


Law Society of Singapore Law Society of New South Wales, Australia Singapore Corporate Counsel Association



National University of Singapore - Part A Bar Exams LLB (Hons), University of Adelaide BCom, University of Adelaide Graduate Diploma in Applied Finance and Investments, Securities Institute of Australia



Year First Admitted To Bar


Languages Spoken

English (GB)

Languages Written

English (GB)

   About Me

Faith is an experienced corporate and commercial lawyer. She provides legal representation for clients in the Asia Pacific region. Faith has over 15 years'​ experience helping clients successfully structure, negotiate and document corporate and commercial deals, completing transactions with a combined value exceeding US$30 billion. Faith understands how businesses operate - she worked alongside other management team members to bed down a major merger and set up a legal department, as the first General Counsel of Aspen Pharmacare Australia. Faith has worked in top corporate law firms in Sydney and London, including working on complex and innovative transactions requiring cutting-edge technical excellence. Faith currently consult to Allen & Overy in addition to providing services through fsLAW. fsLAW is a boutique business law firm structured to provide quality legal representation with consistently competitive prices. We look to build long term relationships with clients who value: - corporate history retention; - consistency of service quality; - a relationship with a trusted legal advisor. In return, we keep our prices competitive by keeping our structure simple and costs low. You can afford to work with us today, tomorrow and over the coming years. fsLAW's clients include Insurance Australia Group and ExoCyte Therapeutics.